Sisu Pharma is developing selective HSF1 degraders that target the Heat Shock Factor 1 transcription factor to treat therapy-resistant prostate cancer. This approach leverages the cellular stress response to provide effective treatment options where existing therapies fail.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, including prostate cancer, develop resistance to existing therapies, creating a need for new treatment options. Current treatments often fail to address the underlying mechanisms that allow cancer cells to survive and proliferate under stress.
Solution
Sisu Pharma is developing selective Heat Shock Factor 1 (HSF1) degraders to combat therapy-resistant cancers. The company's HI-LiTe platform directly targets HSF1, a key regulator of the cellular stress response, to selectively degrade HSF1 in cancer cells. By exploiting the stress protection response, Sisu Pharma's compounds have demonstrated efficacy in preclinical models where existing treatments have failed. The HI-LiTe platform also offers potential for developing therapies for neurodegenerative diseases and infections.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking novel therapeutic approaches for therapy-resistant cancers, as well as pharmaceutical companies interested in licensing or partnering to develop new cancer treatments.
Features
- HI-LiTe platform for selective targeting and degradation of HSF1
- First-in-class HSF1 degraders with demonstrated efficacy in therapy-resistant cancer models
- Potential applications in oncology, neurodegenerative diseases, and infections